Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 22,451 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pathological Processes Clear all
Terminated Not applicable Interventional

Selenium Supplementation of Patients With Cirrhosis

NCT00212212
View directory record Official record
Conditions
Cirrhosis
Interventions
selenium, placebo
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Oct 24, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

NCT07657312
View directory record Official record
Conditions
Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Naresh Bumma
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 24, 2026, 2:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Elironrasib, Daraxonrasib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
23
States / cities
Duarte, California • Orange, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 24, 2026, 2:42 PM EDT
Active, not recruiting Phase 1 Interventional

Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT

NCT00840853
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma
Interventions
CD19CAR/virus specific T cells, Benadryl and Tylenol
Genetic · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2031
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 24, 2026, 2:42 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Active and Healthy Brotherhood: A Program for Chronic Disease Self-Management for Black Men

NCT02362737
View directory record Official record
Conditions
Chronic Disease, Obesity, Hypertension, Diabetes, Self Care, Medication Adherence
Interventions
Active and Healthy Brotherhood (AHB)
Behavioral
Lead sponsor
Gramercy Research Group
Other
Eligibility
21 Years to 64 Years · Male only
Enrollment
332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 24, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

NCT00509145
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Laquinimod, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
23
States / cities
Phoenix, Arizona • Centennial, Colorado • Fort Collins, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 24, 2026, 2:42 PM EDT
Not listed Phase 2 Interventional

Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)

NCT04847739
View directory record Official record
Conditions
Perianal Fistula, Crohn's Disease
Interventions
Seton Placement, AVB-114
Procedure · Drug
Lead sponsor
Avobis Bio, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Redwood City, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 24, 2026, 2:42 PM EDT
Recruiting No phase listed Observational

Boston Birth Cohort Study

NCT03228875
View directory record Official record
Conditions
Maternal Health, Child Health, Pregnancy Complications, Birth Outcome, Adverse
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
0 Years to 50 Years
Enrollment
24,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 2:42 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

NCT04317105
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Echocardiography Test, Ipilimumab, Nivolumab, X-Ray Imaging
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • Austin, Texas • Galveston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 24, 2026, 2:42 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment

NCT06805994
View directory record Official record
Conditions
Staphylococcal Aureus Infection, Microbial Colonization, Pediatric Infection, S. Aureus Colonization, Microbial Transplant
Interventions
Nasal Microbiota Transplant (NMT), Placebo
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
0 Years to 60 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 24, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

NCT00685529
View directory record Official record
Conditions
COPD
Interventions
Racemic formoterol, Arformoterol tartrate inhalation solution
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
Long Beach, California • Fort Lauderdale, Florida • Raleigh, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 24, 2026, 2:42 PM EDT
Completed Not applicable Interventional Results available

Aerobic Exercise for Remyelination in Multiple Sclerosis

NCT04539002
View directory record Official record
Conditions
Multiple Sclerosis, Sclerosis, Demyelinating Diseases, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Autoimmune Diseases, CNS, Exercise
Interventions
Aerobic exercise, Education Group Control
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 24, 2026, 2:42 PM EDT
Completed No phase listed Observational

Study to Determine Quicker Methods of Diagnosing Pneumonia Caused by a Breathing Machine in Critically Ill Patients

NCT00938002
View directory record Official record
Conditions
Ventilator Acquired Pneumonia
Interventions
Acceler8 Pheno
Diagnostic Test
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 24, 2026, 2:42 PM EDT
Active, not recruiting Phase 4 Interventional

Exparel Injection for Postoperative Orbital Pain

NCT02381353
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Bupivacaine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 24, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

NCT06839053
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gastrointestinal Endoscopy, Rituximab, Sonrotoclax, Zanubrutinib
Procedure · Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 24, 2026, 2:42 PM EDT
Completed Phase 4 Interventional Results available

Study of Oral Treatments for Hepatitis C

NCT02786537
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir), Ribavirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
1,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
38
States / cities
Little Rock, Arkansas • Palo Alto, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 24, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

NCT00005639
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Azacitidine Injection, sodium phenylbutyrate
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 24, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery

NCT00004075
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tanespimycin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 24, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Contingency Management to Improve Medication for Opioid Use Disorder Continuation After the Emergency Department

NCT07129902
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Contingency Management, Usual care as prescribed by the ED physicians
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 2:42 PM EDT
Completed No phase listed Observational

Collection of Heart Tissue Sample During Open Heart Surgery

NCT00423553
View directory record Official record
Conditions
Ischemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)

NCT04724837
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Zibotentan, Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
50
States / cities
Huntsville, Alabama • Beverly Hills, California • Downey, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 24, 2026, 2:42 PM EDT
Recruiting Phase 1 Interventional

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

NCT06904066
View directory record Official record
Conditions
Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms, Hematopoietic Malignancies, Dysmyelopoietic Syndromes, Hematopoetic Myelodysplasia, Myeloid Leukemia, Acute, Nonlymphoblastic Leukemia, Acute, Leukemia, Lymphocytic, Acute
Interventions
aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500
Drug · Biological · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 2:42 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan

NCT05025956
View directory record Official record
Conditions
Femoroacetabular Impingement
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 24, 2026, 2:42 PM EDT
Completed No phase listed Observational

A Clinical Investigation of the C2a-Taper™ Acetabular System

NCT00578851
View directory record Official record
Conditions
Osteoarthritis, Avascular Necrosis, Congenital Hip Dysplasia, Traumatic Arthritis
Interventions
C2a - Taper™ Acetabular System
Device
Lead sponsor
Biomet Orthopedics, LLC
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
Cedar Rapids, Iowa • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 24, 2026, 2:42 PM EDT